Moneycontrol PRO
HomeNewsBusinessCompaniesDr Reddy's launches OTC drug in the US market

Dr Reddy's launches OTC drug in the US market

Dr Reddy's Laboratories today said it has launched two over-the-counter (OTC) drugs used to treat seasonal allergies such as itchy nose and sneezing, in the US market.

August 30, 2011 / 21:52 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Dr Reddy's Laboratories today said it has launched two over-the-counter (OTC) drugs used to treat seasonal allergies such as itchy nose and sneezing, in the US market.


    Fexofenadine HCl and Pseudoephedrine HCl extended release tablets in the strengths of 180 and 240 mg have been released in the US market, Dr Reddy's Laboratories said in a statement.


    OTC drugs can be purchased without a prescription and are commonly used to treat symptoms of common illnesses that may not require the direct supervision of a physician.


    The US Food and Drug Administration (USFDA) had approved the Hyderabad-based firm's abbreviated new drug application (ANDA) for the tablets on June 22, 2011, it added.


    "Dr Reddy's will market the product under store brand labels in the US market," the company said.


    The company's product is a bio equivalent version of Sanofi Aventis' Allegra D24 Hour extended release tablets, it said.


    Shares of Dr Reddy's Laboratories today closed at Rs 1,493.85 on the Bombay Stock Exchange, up 1.89% from previous close.

    first published: Aug 30, 2011 09:14 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
    CloseGen AI Masterclass